Amgen Hones In On Denosumab Sales And Payer Strategies Ahead Of Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech estimates 500 to 1,000 sales reps will be needed to commercialize the osteoporosis injectable in the U.S.